Tylenol Arthritis Sales Provide J&J Some Buffer From Currency Headwinds
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson’s US consumer segment sales grow 7.7% to $3.31bn, fueled by 29% growth of analgesics products. Currency headwinds continue to hammer the firm’s overall performance, while management seeks to ensure investors the business is healthy despite effects.
You may also be interested in...
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.
MoCRA Implementation In US Election Year: Q&A With Attorney Wade Ackerman
Wade Ackerman, partner at Covington & Burling who served previously as senior FDA counsel to US Senate Health Education, Labor & Pensions (HELP) Committee leadership, discusses expectations for FDA activity under modernized cosmetics regulations in 2024.
Ulta’s Footprint Will Grow From US To Mexico In 2025 Under Axo Partnership
Bolingbrook, Ill.-based Ulta Beauty, Inc. will make its international debut in Mexico, a "sizable, growing” market that represents "significant beauty opportunity," says CEO David Kimbell in the firm’s a fiscal 2023 fourth-quarter earnings presentation.